Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Risk stratification of newly diagnosed AML receiving nonintensive treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJi Yun LeeJLJeong Ok LeeSBSoo‐Mee Bang

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds significant prognostic factors in AML, highlighting the need for improved risk scores.

Key Points

  • Overall survival was markedly different between risk groups, with median survival of 13.7 months in low-risk versus 2.5 months in high-risk patients.
  • Patients were evaluated based on prognostic factors including TP53 mutation, which was linked to poorer outcomes.
  • Retrospective analysis assessed risk categorization using the ELN 2022 and 2024 systems for AML patients receiving nonintensive treatment.
  • Findings suggest that existing ELN classifications require refinement for better risk stratification in nonintensively treated AML.

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5c0https://doi.org/10.1182/blood-2025-6910
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population2025
  2. 2Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study2025
  3. 3Prognostic evaluation of ELN-2022 and ELN-2024 risk stratification in newly diagnosed AML patients and development of a novel genetic risk model2025
  4. 4TP53, EZH2, or RUNX1 mutations predict poor outcomes in ELN 2022 adverse risk group of adult AML patients undergoing allo-HSCT2025
  5. 5Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax2025